Verrica Pharmaceuticals Inc. (VRCA) Tops Q4 EPS by 6c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q4 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $340 thousand versus the consensus estimate of $532.75 thousand.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Morgan Stanley Starts Target Hospitality (TH) at Overweight
• Allogene (ALLO) Reiterated at Market Outperform by Citizens: 'ALPHA3 Trial is On-Track'